Moderna's 'surprise' IP court order could set up a big settlement for Roivant, Arbutus — analysts
The battle over who owns the patented lipid nanoparticle technology that carried the Covid-19 vaccines across the finish line and into millions of people’s arms remains in heated dispute. But a new court order adds an unexpected twist that could see the mRNA powerhouse Moderna paying a hefty sum to settle complaints from two smaller companies that originally licensed the LNP tech to Moderna.
In their original complaint, those two companies — Arbutus and Genevant Sciences (partially owned by Arbutus and Vivek Ramaswamy’s Roivant) — acknowledged that Moderna brought its life-saving Covid vaccine “from lab bench to arms in record speed,” but that would not have been possible without the use of Arbutus’ LNP delivery platform, which “took the scientists of Arbutus years of painstaking work to develop and refine.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.